A Systematic Review of Metachromatic Leukodystrophy Newborn Screening: Transitioning from Pilot Studies to the Real World
International Journal of Neonatal Screening · 17.10.2026 · 12 (4) · 86
DOI: 10.3390/ijns12040086 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Neonatal Screening, online erschienen am 17.10.2026. Verfasst von Samuel Waser und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Children's Hospital Aarau (KSA), 5000 Aarau, Switzerland. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Council Forschungsrat Kantonsspital Aarau, Research Council KSA—Kantonsspital Aarau.
Abstract (Originalsprache)
Metachromatic leukodystrophy (MLD) is a rare lysosomal storage disorder causing progressive neurodegeneration through central and peripheral demyelination, leading to premature death. Recent advances in ex vivo lentiviral gene therapy have developed a potentially curative treatment approach for pre-symptomatic infants with early-onset MLD. This systematic review evaluates the current evidence regarding newborn screening (NBS) for MLD, including screening methodologies, diagnostic pathways, and implementation challenges, using the Swiss healthcare system as an illustrative example. A literature search using keywords MLD and NBS was conducted across five databases on 29 September 2025 and updated on 21 September 2026, along with contacting leading experts of the field up to 1 July 2026, resulting in the inclusion of 27 publications and six conference papers. Multi-tiered screening algorithms combining sulfatide species quantification, second-tier enzyme activity measurement, and genetic confirmation testing can reliably identify MLD-affected infants while reducing false-positive results. Pilot studies and early national implementation programs have confirmed the feasibility of population-based MLD NBS. We consider Switzerland well positioned to integrate MLD into its centralized national NBS program. Several factors, including achieving cost-effectiveness, subtype prediction, and management of uncertain cases, require thorough consideration and represent potentially universal barriers to widespread adoption of MLD NBS beyond pilot programs around the world.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Children's Hospital Aarau (KSA), 5000 Aarau, Switzerland.
- University Children's Hospital Zurich, 8008 Zurich, Switzerland.
- Faculty of Medicine, University of Basel, 4056 Basel, Switzerland.
- Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
- Division of Pediatric Blood and Marrow Transplantation and Cellular Therapy, University of Minnesota, Minneapolis, MN 55454, USA.
- Pediatric Neurology, Developmental Pediatrics and Neurorehabilitation of Northwestern Switzerland, University Children's Hospital Basel (UKBB), Basel and Children's Hospital Aarau (KSA), 5000 Aarau, Switzerland.
ORCID-Profile: Samuel Waser, Laura A Adang, Paul J Orchard, Neal Sondheimer, Henrik Köhler
Förderung
- Research Council Forschungsrat Kantonsspital Aarau
- Research Council KSA—Kantonsspital Aarau
Zitieren
APA
Waser, S., Kistler, S., Adang, L. A., Orchard, P. J., Datta, A. N., Sondheimer, N., Köhler, H., & Drozdov, D. (2026). A Systematic Review of Metachromatic Leukodystrophy Newborn Screening: Transitioning from Pilot Studies to the Real World. International Journal of Neonatal Screening, 12(4), 86. https://doi.org/10.3390/ijns12040086
Vancouver
Waser S, Kistler S, Adang LA, Orchard PJ, Datta AN, Sondheimer N, et al. A Systematic Review of Metachromatic Leukodystrophy Newborn Screening: Transitioning from Pilot Studies to the Real World. International Journal of Neonatal Screening. 2026;12(4):86. doi:10.3390/ijns12040086
BibTeX
@article{Waser2026,
author = {Waser, Samuel and Kistler, Simone and Adang, Laura A and Orchard, Paul J and Datta, Alexandre N and Sondheimer, Neal and Köhler, Henrik and Drozdov, Daniel},
title = {A Systematic Review of Metachromatic Leukodystrophy Newborn Screening: Transitioning from Pilot Studies to the Real World},
journal = {International Journal of Neonatal Screening},
year = {2026},
volume = {12},
number = {4},
pages = {86},
doi = {10.3390/ijns12040086}
}
EUVIMED